How long should I continue apixaban (Eliquis) after surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Timing of Apixaban Resumption After Surgery

Resume apixaban 24 hours after low-bleeding-risk surgery or 48-72 hours after high-bleeding-risk surgery, once adequate hemostasis is established. 1, 2

Surgical Bleeding Risk Stratification

The timing of apixaban resumption depends critically on the bleeding risk of your procedure:

Low-to-Moderate Bleeding Risk Surgery

  • Resume at 24 hours postoperatively at full dose (5 mg twice daily) 1
  • Examples: most laparoscopic procedures, minor orthopedic surgery, dental procedures
  • Ensure adequate wound hemostasis before restarting

High Bleeding Risk Surgery

  • Resume at 48-72 hours postoperatively at full dose (5 mg twice daily) 1
  • Examples: major abdominal surgery, neurosurgery, spinal procedures, major orthopedic surgery
  • For patients at very high thrombotic risk, consider reduced-dose apixaban (2.5 mg twice daily) starting earlier, then escalate to full dose after 2-3 days 1

Special Considerations for High Thrombotic Risk Patients

If your patient has high thrombotic risk (mechanical heart valve, recent VTE, high CHADS₂ score ≥5):

  • Consider bridging with prophylactic-dose LMWH (enoxaparin 40 mg daily) starting 6-24 hours postoperatively 3, 4
  • Transition to reduced-dose apixaban (2.5 mg twice daily) at 48 hours, then full dose at 72 hours 1
  • Do not use therapeutic-dose bridging - this significantly increases bleeding risk without proven benefit 3

Duration of Extended Prophylaxis

The question of "how long" has two interpretations:

For Patients on Chronic Anticoagulation (Atrial Fibrillation, Prior VTE)

  • Resume apixaban as outlined above and continue indefinitely based on the underlying indication 2
  • The FDA label specifies continuing apixaban for stroke prevention in AF or VTE treatment as long as the indication persists 2

For Surgical VTE Prophylaxis Only

  • 12 days for knee replacement surgery 2
  • 35 days for hip replacement surgery 2
  • 28-30 days for major abdominal/pelvic cancer surgery 4, 5, 6
  • Recent evidence supports 14-30 day prophylaxis for bariatric surgery with excellent safety profiles 7, 8, 9

Critical Timing Details

Apixaban has rapid onset (peak effect 1-3 hours) 1, making it similar to therapeutic-dose LMWH. This is why cautious, delayed resumption is essential after high-bleeding-risk procedures.

Common Pitfalls to Avoid:

  • Never resume full-dose apixaban immediately postoperatively - the rapid anticoagulant effect increases bleeding risk 1
  • Avoid neuraxial anesthesia/procedures if apixaban was recently taken - ensure at least 48-72 hours have elapsed since last dose 4
  • Do not double-dose if a dose is missed - simply resume the regular schedule 2
  • Bowel surgery patients may have delayed absorption - this typically resolves within 24-72 hours and is not clinically significant 1

Practical Algorithm

  1. Assess surgical bleeding risk (low vs. high)
  2. Confirm adequate hemostasis at surgical site
  3. Low-risk surgery: Resume apixaban 5 mg twice daily at 24 hours
  4. High-risk surgery: Resume apixaban 5 mg twice daily at 48-72 hours
  5. Very high thrombotic risk + high bleeding risk: Consider prophylactic LMWH bridge, then reduced-dose apixaban (2.5 mg twice daily) at 48 hours, escalating to full dose at 72 hours
  6. Continue duration based on indication (indefinite for AF/VTE, or procedure-specific prophylaxis duration)

The 2012 Blood guidelines 1 and 2017 French GIHP guidelines 4 provide the most comprehensive framework, while the 2022 CHEST guidelines 10 and FDA label 2 confirm these recommendations remain current standard of care.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.